MeiraGTx Holdings (MGTX) Financials: History & Chart

MeiraGTx Holdings plc(MGTX)

Biotechnology · New York City, NY

$10.56-0.36 (-3.31%)

Delayed quote: Oct 6, 2026, 1:35 PM EDT

About MeiraGTx Holdings plc

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

New York City, NY

393 employees

www.meiragtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alexandria Forbes

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	397.50M	321.43M	293K	75.36M	410K	3.69M	1.93M	21.39M	10.91M
Cost of Goods Sold	11.16M	7.16M	3.21M	476K	313K	2.68M	1.38M	11.81M	11.98M
Gross Profit	386.34M	314.27M	-2.91M	74.89M	97K	1.01M	548K	9.58M	-1.07M
Gross Profit Margin	97.2%	97.8%	-994.2%	99.4%	23.7%	27.5%	28.5%	44.8%	-9.9%
Total Operating Expenses	202.31M	69.84M	37.90M	48.42M	46.15M	45.81M	42.14M	41.07M	38.97M
Research & Development	153.16M	57.83M	31.98M	30.81M	32.53M	33.49M	32.78M	23.98M	26.24M
Selling, General & Administrative	52.16M	12.01M	8.93M	17.60M	13.62M	12.31M	9.36M	20.36M	12.72M
Operating Income (EBIT)	184.03M	244.43M	-40.82M	26.47M	-46.05M	-44.79M	-41.60M	-31.49M	-40.04M
Operating Margin	46.3%	76.0%	-13930.7%	35.1%	-11232.0%	-1213.6%	-2159.7%	-147.2%	-367.0%
Income Before Tax (EBT)	81.29M	163.03M	-46.31M	15.09M	-50.51M	-38.80M	-39.98M	-39.40M	-39.33M
Interest Income	1.33M	706K	189K	278K	161K	408K	971K	1.03M	1.19M
Interest Expense	12.48M	3.51M	2.85M	3.06M	3.06M	3.03M	3.04M	3.41M	3.36M
Other Income/Expense	-102.74M	-81.39M	-5.50M	-11.38M	-4.46M	6.00M	1.61M	-7.91M	711K
Net Income	78.98M	160.72M	-46.31M	15.09M	-50.51M	-38.80M	-39.98M	-39.40M	-39.33M
Income Tax Expense	2.36M	2.36M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	19.9%	50.0%	-15806.5%	20.0%	-12320.2%	-1051.1%	-2075.9%	-184.2%	-360.5%
EBITDA	196.48M	247.25M	-37.81M	29.65M	-42.61M	-41.60M	-38.52M	-28.57M	-36.78M
EBITDA Margin	49.4%	76.9%	-12904.1%	39.3%	-10393.4%	-1127.1%	-1999.7%	-133.5%	-337.1%
Depreciation & Amortization	12.45M	2.82M	3.01M	3.18M	3.44M	3.19M	3.08M	2.92M	3.26M
EPS Basic	0.76	1.76	-0.57	0.19	-0.62	-0.48	-0.51	-0.50	-0.55
EPS Diluted	0.71	1.71	-0.57	0.19	-0.62	-0.48	-0.51	-0.50	-0.55
Weighted Average Basic Shares	91.42M	91.42M	81.30M	81.12M	80.95M	80.59M	79.03M	69.82M	71.63M
Weighted Average Diluted Shares	93.81M	93.81M	81.30M	81.12M	80.95M	80.59M	79.03M	69.82M	71.63M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	81.39M	33.28M	14.02M	15.92M	37.70M	15.56M	13.29M	0.00
Cost of Goods Sold	4.84M	23.79M	0.00	0.00	0.00	0.00	0.00	2.05M
Gross Profit	76.55M	9.49M	14.02M	15.92M	37.70M	15.56M	13.29M	-2.05M
Gross Profit Margin	94.0%	28.5%	100.0%	100.0%	100.0%	100.0%	100.0%	N/A
Total Operating Expenses	182.52M	173.70M	151.08M	132.28M	110.46M	78.12M	71.56M	78.10M
Research & Development	129.62M	119.48M	103.78M	85.72M	66.69M	33.91M	24.88M	33.62M
Selling, General & Administrative	52.90M	54.22M	47.29M	46.55M	43.77M	44.21M	46.68M	44.48M
Operating Income (EBIT)	-105.97M	-164.21M	-137.06M	-116.36M	-72.76M	-62.55M	-58.27M	-78.10M
Operating Margin	-130.2%	-493.4%	-977.8%	-730.9%	-193.0%	-401.9%	-438.4%	N/A
Income Before Tax (EBT)	-114.20M	-147.79M	-84.03M	-129.62M	-79.56M	-57.99M	-54.75M	-83.34M
Interest Income	1.82M	4.14M	2.27M	777K	212K	1.28M	371K	53K
Interest Expense	12.20M	13.27M	13.24M	4.95M	288K	139K	49K	33K
Other Income/Expense	-8.23M	16.42M	53.03M	-13.26M	-6.80M	4.56M	3.52M	-5.24M
Net Income	-114.20M	-147.79M	-84.03M	-129.62M	-79.56M	-57.99M	-54.75M	-82.87M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-474K
Net Profit Margin	-140.3%	-444.1%	-599.5%	-814.2%	-211.0%	-372.6%	-411.9%	N/A
EBITDA	-93.36M	-151.38M	-123.33M	-107.75M	-64.89M	-58.38M	-56.03M	-76.05M
EBITDA Margin	-114.7%	-454.9%	-879.9%	-676.8%	-172.1%	-375.1%	-421.5%	N/A
Depreciation & Amortization	12.61M	12.83M	13.73M	8.60M	7.87M	4.17M	2.24M	2.05M
EPS Basic	-1.42	-2.12	-1.49	-2.87	-1.80	-1.43	-1.58	-4.37
EPS Diluted	-1.42	-2.12	-1.49	-2.87	-1.80	-1.43	-1.58	-4.37
Weighted Average Basic Shares	80.43M	69.82M	56.49M	45.18M	44.14M	37.72M	33.16M	18.95M
Weighted Average Diluted Shares	80.43M	69.82M	56.49M	45.18M	44.14M	37.72M	33.16M	18.95M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.